April 16, 2021
RFA-CA-22-045 - NCI Outstanding Investigator Award (R35 Clinical Trial Optional).
NOT-CA-17-006 - Notice on Award Administration Information for the NCI Outstanding Investigator Award (R35) (RESCINDED)
National Cancer Institute (NCI)
The purpose of this Notice is to clarify and update the information previously provided in NOT-CA-17-006, "Notice of Award Administration Information for the NCI Outstanding Investigator Award (R35)", which is now rescinded. As previously stated in NOT-CA-17-006, "Notice on Award Administration Information for the NCI Outstanding Investigator Award (R35)", applications submitted after the Outstanding Investigator Award (OIA) is awarded will not be folded into the R35 award; however, the 6 calendar month level of effort on the OIA must be maintained for the entire 7-year project period.
While the OIA is active, NCI will only consider funding two additional research awards on which the Outstanding Investigator is a named PD/PI. Research awards include single PD/PI, multiple PD/PI, multi-project grants, and Cancer Center (P30) grants, as well as Cancer Grand Challenges (CGC) awards where the OIA recipient is the CGC Team Lead. Other non-PD/PI roles, such as Project Leader or Co-Investigator are not considered in the two additional research awards.
The NCI will not approve a change of PD/PI on a peer reviewed and approved NCI grant to avoid these OIA requirements.
Specific to R35 renewal (Type 2) awards: An OIA investigator who was awarded two additional NCI research awards during the prior OIA project period will not be awarded another NCI grant or CGC award while those research awards are active. In addition, those research awards do not need to be relinquished when the renewal OIA (R35) is awarded. In other words, an OIA investigator may only have two additional NCI funded research awards.